Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | ROS1 | P08922 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21375765 | 0.88 | TGFBR1 (0.44) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL5907474 | 0.88 | TGFBR1 (0.46) | TGFBR1MAPK14ROS1KDRRIPK2 | |
| SCHEMBL5907522 | 0.87 | MAT2A (0.43) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL12645997 | 0.87 | TGFBR1 (0.61) | TGFBR1MAPK14THRBNPC1RAB9A | |
| Gw679410X SCHEMBL376414 | 0.86 | TGFBR1 (0.63) | TGFBR1ROS1DYRK1AMAPKAPK2THRB | |
| SCHEMBL5907483 | 0.85 | TGFBR1 (0.48) | TGFBR1MAPK14KDRRIPK2MAPKAPK2 | |
| SCHEMBL21932018 | 0.85 | TGFBR1 (0.41) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL31373673 | 0.85 | TGFBR1 (0.40) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL29528228 | 0.85 | TGFBR1 (0.41) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL5907469 | 0.84 | TGFBR1 (0.62) | TGFBR1MAPK14KDRRIPK2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058329-A1 | Pyrazole inhibitors of the transforming growth factor | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058329-A1 | Pyrazole inhibitors of the transforming growth factor | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885MAPK14 148/4885ROS1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.